Statement of Ownership (sc 13g)
15 2월 2022 - 2:14AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. )*
Viracta Therapeutics, Inc.
(Name of Issuer)
Common
Stock
(Title of Class of Securities)
92765F108
(CUSIP Number)
December 31, 2021
(Date of Event Which Requires Filing of this Statement)
Check the Appropriate Box to
Designate the Rule Pursuant to Which this Schedule Is Filed:
☐ Rule 13d-1(b)
☐ Rule 13d-1(c)
☒ Rule 13d-1(d)
|
*
|
The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form
with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
|
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities
Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
|
|
|
|
|
|
|
|
|
1.
|
|
Names of Reporting Persons
Aisling Capital IV, LP
|
|
2.
|
|
Check The Appropriate Box
if a Member of a Group (See Instructions)
(a) ☐ (b) ☐
|
|
3.
|
|
SEC Use Only
|
|
4.
|
|
Citizenship or Place of
Organization
Delaware
|
|
|
|
|
|
|
|
|
|
Number of
Shares
Beneficially
Owned By
Each
Reporting
Person
With
|
|
5.
|
|
Sole Voting Power
0
|
|
|
6.
|
|
Shared Voting Power
288,571
|
|
|
7.
|
|
Sole Dispositive Power
0
|
|
|
8.
|
|
Shared Dispositive Power
288,571
|
|
|
|
|
|
|
|
|
|
9.
|
|
Aggregate Amount Beneficially Owned by Each Reporting Person
288,571
|
|
10.
|
|
Check Box if the Aggregate
Amount in Row (9) Excludes Certain Shares
☐
|
|
11.
|
|
Percent of Class
Represented By Amount in Row (9)
0.77%(1)
|
|
12.
|
|
Type of Reporting Person
(See Instructions)
PN
|
|
(1)
|
Calculated based on 37,311,960 shares of Common Stock outstanding as of November 3, 2021 as reported on
the Issuer’s Form 10-Q, filed on November 10, 2021.
|
|
|
|
|
|
|
|
|
|
1.
|
|
Names of Reporting Persons
Aisling Capital Partners IV LLC
|
|
2.
|
|
Check The Appropriate Box
if a Member of a Group (See Instructions)
(a) ☐ (b) ☐
|
|
3.
|
|
SEC Use Only
|
|
4.
|
|
Citizenship or Place of
Organization
Delaware
|
|
|
|
|
|
|
|
|
|
Number of
Shares
Beneficially
Owned By
Each
Reporting
Person
With
|
|
5.
|
|
Sole Voting Power
0
|
|
|
6.
|
|
Shared Voting Power
288,571
|
|
|
7.
|
|
Sole Dispositive Power
0
|
|
|
8.
|
|
Shared Dispositive Power
288,571
|
|
|
|
|
|
|
|
|
|
9.
|
|
Aggregate Amount Beneficially Owned by Each Reporting Person
288,571
|
|
10.
|
|
Check Box if the Aggregate
Amount in Row (9) Excludes Certain Shares
☐
|
|
11.
|
|
Percent of Class
Represented By Amount in Row (9)
0.77%(1)
|
|
12.
|
|
Type of Reporting Person
(See Instructions)
OO
|
|
(1)
|
Calculated based on 37,311,960 shares of Common Stock outstanding as of November 3, 2021 as reported on
the Issuer’s Form 10-Q, filed on November 10, 2021.
|
|
|
|
|
|
|
|
|
|
1.
|
|
Names of Reporting Persons
Aisling Capital Partners IV, LP
|
|
2.
|
|
Check The Appropriate Box
if a Member of a Group (See Instructions)
(a) ☐ (b) ☐
|
|
3.
|
|
SEC Use Only
|
|
4.
|
|
Citizenship or Place of
Organization
Delaware
|
|
|
|
|
|
|
|
|
|
Number of
Shares
Beneficially
Owned By
Each
Reporting
Person
With
|
|
5.
|
|
Sole Voting Power
0
|
|
|
6.
|
|
Shared Voting Power
288,571
|
|
|
7.
|
|
Sole Dispositive Power
0
|
|
|
8.
|
|
Shared Dispositive Power
288,571
|
|
|
|
|
|
|
|
|
|
9.
|
|
Aggregate Amount Beneficially Owned by Each Reporting Person
288,571
|
|
10.
|
|
Check Box if the Aggregate
Amount in Row (9) Excludes Certain Shares
☐
|
|
11.
|
|
Percent of Class
Represented By Amount in Row (9)
0.77%(1)
|
|
12.
|
|
Type of Reporting Person
(See Instructions)
PN
|
|
(1)
|
Calculated based on 37,311,960 shares of Common Stock outstanding as of November 3, 2021 as reported on
the Issuer’s Form 10-Q, filed on November 10, 2021.
|
|
|
|
|
|
|
|
|
|
1.
|
|
Names of Reporting Persons
Steve Elms
|
|
2.
|
|
Check The Appropriate Box
if a Member of a Group (See Instructions)
(a) ☐ (b) ☐
|
|
3.
|
|
SEC Use Only
|
|
4.
|
|
Citizenship or Place of
Organization
United States of
America
|
|
|
|
|
|
|
|
|
|
Number of
Shares
Beneficially
Owned By
Each
Reporting
Person
With
|
|
5.
|
|
Sole Voting Power
0
|
|
|
6.
|
|
Shared Voting Power
288,571
|
|
|
7.
|
|
Sole Dispositive Power
0
|
|
|
8.
|
|
Shared Dispositive Power
288,571
|
|
|
|
|
|
|
|
|
|
9.
|
|
Aggregate Amount Beneficially Owned by Each Reporting Person
288,571
|
|
10.
|
|
Check Box if the Aggregate
Amount in Row (9) Excludes Certain Shares
☐
|
|
11.
|
|
Percent of Class
Represented By Amount in Row (9)
0.77%(1)
|
|
12.
|
|
Type of Reporting Person
(See Instructions)
IN
|
|
(1)
|
Calculated based on 37,311,960 shares of Common Stock outstanding as of November 3, 2021 as reported on
the Issuer’s Form 10-Q, filed on November 10, 2021.
|
|
|
|
|
|
|
|
|
|
1.
|
|
Names of Reporting Persons
Andrew N. Schiff
|
|
2.
|
|
Check The Appropriate Box
if a Member of a Group (See Instructions)
(a) ☐ (b) ☐
|
|
3.
|
|
SEC Use Only
|
|
4.
|
|
Citizenship or Place of
Organization
United States of
America
|
|
|
|
|
|
|
|
|
|
Number of
Shares
Beneficially
Owned By
Each
Reporting
Person
With
|
|
5.
|
|
Sole Voting Power
0
|
|
|
6.
|
|
Shared Voting Power
288,571
|
|
|
7.
|
|
Sole Dispositive Power
0
|
|
|
8.
|
|
Shared Dispositive Power
288,571
|
|
|
|
|
|
|
|
|
|
9.
|
|
Aggregate Amount Beneficially Owned by Each Reporting Person
288,571
|
|
10.
|
|
Check Box if the Aggregate
Amount in Row (9) Excludes Certain Shares
☐
|
|
11.
|
|
Percent of Class
Represented By Amount in Row (9)
0.77%(1)
|
|
12.
|
|
Type of Reporting Person
(See Instructions)
IN
|
|
(1)
|
Calculated based on 37,311,960 shares of Common Stock outstanding as of November 3, 2021 as reported on
the Issuer’s Form 10-Q, filed on November 10, 2021..
|
|
|
|
|
|
Item 1(a).
|
|
Name of Issuer
|
|
|
|
|
|
|
Viracta Therapeutics, Inc. (the “Issuer”)
|
|
|
|
|
Item 1(b).
|
|
Address of the Issuer’s Principal Executive Offices
|
|
|
|
|
|
|
2533 S. Coast Hwy 101, Suite 210
Cardiff, CA
92007
|
|
|
|
|
Item 2(a).
|
|
Names of Persons Filing
|
|
|
|
|
|
|
This statement is filed by the entities and persons listed below, all of whom together are referred to herein as the “Reporting
Persons”:
(i) Aisling Capital
IV, LP
(ii) Aisling Capital
Partners IV LLC
(iii) Aisling
Capital Partners IV, LP
(iv) Steve
Elms
(v) Andrew N.
Schiff
|
|
|
|
|
Item 2(b).
|
|
Address of the Principal Business Office, or if none, Residence:
|
|
|
|
|
|
|
C/O Aisling Capital Management LP
888 Seventh
Ave., 12th Floor
New York, NY 10106
|
|
|
|
|
Item 2(c).
|
|
Citizenship
|
|
|
|
|
|
|
See responses to Item 4 on each cover page.
|
|
|
|
|
Item 2(d).
|
|
Title of Class of Securities
|
|
|
|
|
|
|
Common Stock
|
|
|
|
|
Item 2(e).
|
|
CUSIP Number
|
|
|
|
|
|
|
92765F108
|
|
|
|
|
Item 3.
|
|
If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a(n):
|
|
|
|
|
|
|
Not Applicable.
|
|
|
|
|
Item 4.
|
|
Ownership
|
|
|
|
|
|
|
(a) Amount beneficially owned: See responses to Item 9 on each cover
page.
(b) Percent of Class:
See responses to Item 11 on each cover page.
(c) Number of shares as to which the Reporting Person has:
(i) Sole power to vote or to direct the
vote:
See responses to Item 5 on each cover page.
(ii) Shared power to vote or to
direct the vote:
See responses to Item 6 on each cover
page.
|
|
|
|
|
|
|
|
(iii) Sole power to dispose or to direct the disposition of:
See responses to Item 7 on each cover page.
(iv) Shared power to dispose or to
direct the disposition of:
See responses to Item 8 on each
cover page.
The securities are directly held by Aisling Capital
IV, LP (“Aisling”). Aisling Capital Partners IV, LP (“Aisling GP”), is the general partner of Aisling, and Aisling Capital Partners IV LLC (“Aisling Partners”), is the general partner of Aisling GP. The managers of
Aisling Partners are Dr. Andrew Schiff and Steve Elms, who share voting power and dispositive powers over securities held by Aisling, and as a result, may each be deemed to have beneficial ownership over such securities. This Statement shall
not be construed as an admission that any of the Reporting Persons are, for purposes of Section 13(d) and 13(g), beneficial owners of the reported securities.
|
|
|
|
|
Item 5.
|
|
Ownership of Five Percent or Less of a Class
|
|
|
|
|
|
|
As of the date of this Statement, each Reporting Person has ceased to be the beneficial owner of more than five percent
of the class of securities.
|
|
|
|
|
Item 6.
|
|
Ownership of More than Five Percent on Behalf of Another Person
|
|
|
|
|
|
|
Not Applicable.
|
|
|
|
|
Item 7.
|
|
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company
|
|
|
|
|
|
|
Not Applicable.
|
|
|
|
|
Item 8.
|
|
Identification and Classification of Members of the Group
|
|
|
|
|
|
|
Not Applicable.
|
|
|
|
|
Item 9.
|
|
Notice of Dissolution of Group
|
|
|
|
|
|
|
Not Applicable.
|
|
|
|
|
Item 10.
|
|
Certification
|
|
|
|
|
|
|
Not Applicable.
|
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Dated: February 14, 2022
|
|
|
|
|
AISLING CAPITAL IV, LP
By
Aisling Capital Partners IV, LP, its
General Partner
By
Aisling Capital Partners IV LLC, its
General Partner
|
|
|
|
|
By:
|
|
/s/ Andrew Schiff
|
|
Name:
|
|
Andrew Schiff
|
|
Title:
|
|
Managing Member
|
EXHIBIT LIST
Exhibit A Joint Filing Agreement, dated as of February 14, 2022
Sunesis Pharmaceuticals (NASDAQ:SNSS)
과거 데이터 주식 차트
부터 3월(3) 2025 으로 3월(3) 2025
Sunesis Pharmaceuticals (NASDAQ:SNSS)
과거 데이터 주식 차트
부터 3월(3) 2024 으로 3월(3) 2025
Sunesis Pharmaceuticals Inc (나스닥)의 실시간 뉴스: 최근 기사 0
More Viracta Therapeutics, Inc. News Articles
